Comparison of cyclosporine A with methylprednisolone for treatment of canine atopic dermatitis: A parallel, blinded, randomized controlled trial

Veterinary Dermatology

Volumn 14, Issue 1, 2003, Pages 11-22

  Steffan, Jean ^a   Alexander, Deborah ^a   Brovedani, Fabienne ^a   Fisch, Roland D ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Allergy; Atopic dermatitis; Canine; Ciclosporin; Corticosteroids; Cyclosporin; Cyclosporine; Dog; Glucocorticoids; Methylprednisolone; Randomized controlled trial

Indexed keywords

ATOPICA; CYCLOSPORIN A; METHYLPREDNISOLONE; ORO MEDROL; ANTIINFLAMMATORY AGENT; CYCLOSPORIN; DERMATOLOGICAL AGENT;

ANIMAL EXPERIMENT; ARTICLE; ATOPIC DERMATITIS; BIOCHEMISTRY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL DISEASE; HEMATOLOGICAL PARAMETERS; NONHUMAN; PRURITUS; SCORING SYSTEM; VOMITING; ANIMAL; ANIMAL DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DOG DISEASE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; FEMALE; MALE; ORAL DRUG ADMINISTRATION; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANIMALIA; CANIS FAMILIARIS;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; CYCLOSPORINE; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOG DISEASES; DOGS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; MALE; METHYLPREDNISOLONE; TREATMENT OUTCOME;

EID: 0037309017     PISSN: 09594493     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3164.2003.00318.x     Document Type: Article

References (32)

1. Olivry, T., Sousa, C.A. The ACVD task force on canine atopic dermatitis (XIX): general principles of therapy. Veterinary Immunology and Immunopathology 2001; 81: 311-16.
2. Olivry, T., Sousa, C.A. The ACVD task force on canine atopic dermatitis (XX): glucocorticoid pharmacotherapy. Veterinary Immunology and Immunopathology 2001; 81: 317-22.
3. Deboer, D.J., Griffin, C.E. The ACVD task force on canine atopic dermatitis (XXI): antihistamine pharmacotherapy. Veterinary Immunology and Immunopathology 2001; 81: 323-30.
4. Marsella, R., Olivry, T. The ACVD task force on canine atopic dermatitis (XXII): nonsteroidal anti-inflammatory pharmacotherapy. Veterinary Immunology and Immunopathology 2001; 81: 331-45.
5. Nagle, T.M., Torres, S.M., Home, K.L. et al. A randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of a Chinese herbal product (P07P) for the treatment of canine atopic dermatitis. Veterinary Dermatology 2001; 12: 265-74.
6. Fontaine, J., Olivry, T. Treatment of canine atopic dermatitis with cyclosporine: a pilot clinical study. Veterinary Record 2001; 148: 662-3.
7. Olivry, T., Steffan, J., Fisch, R.D. et al. Randomized controlled trial of the efficacy of cyclosporine in the treatment of atopic dermatitis in dogs. Journal of the American Veterinary Medical Association 2002; 221: 370-7.
8. Olivry, T., Rivierre, C., Jackson, H.A. et al. Cyclosporine decreases skin lesions and pruritus in dogs with atopic dermatitis: a blinded randomized prednisolone-controlled trial. Veterinary Dermatology 2002; 13: 77-87.
9. Munro, C.S., Levell, N.J., Shuster, S. et al. Maintenance treatment with cyclosporin in atopic eczema. British Journal of Dermatology 1994; 130: 376-80.
10. Zonneveld, I.M., Derie, M.A., Beljaards, R.C. et al. The long-term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimens. British Journal of Dermatology 1996; 135: 15-20.
11. Harper, J.I., Ahmed, I., Barclay, G. et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. British Journal of Dermatology 2000; 142: 52-8.
12. Guaguère, E., Lasvergeres, F., Arfi, L. Efficacy of oral methylprednisolone in the symptomatic treatment of allergic dermatitis [in French]. Pratique Médicale et Chirurgicale de l'Animal de Compagnie 1996; 31: 171-5.
13. Scott, D.W., Miller, W.H., Griffin, C.E. Glucocorticoid hormones. Small Animal Dermatology, 6th edn. Philadelphia: W.B. Saunders, 2001: 244-52.
14. Prélaud, P., Guaguère, E., Alhaidari, Z. et al. Reevaluation of diagnostic criteria of canine atopic dermatitis. Revue de Médecine Vétérinaire 1998; 149: 1057-64.
15. Willemse, T. Atopic skin disease: a review and a reconsideration of diagnostic criteria. Journal of Small Animal Practice 1986; 27: 771-8.
16. Matousek, J.L., Campbell, K.L. Malassezia dermatitis. Compendium on Continuing Education for the Practicing Veterinarian 2002; 24: 224-32.
17. Chesney, C.J. Systematic review of evidence for the prevalence of food sensitivity in dogs. Veterinary Record 2001; 148: 445-8.
18. Salek, M.S., Finlay, A.Y., Luscombe, D.K. et al. Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. A randomized, double-blind, placebo-controlled trial. British Journal of Dermatology 1993; 129: 422-30.
19. Czech, W., Brautigam, M., Weidinger, G. et al. A bodyweight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. Journal of the American Academy of Dermatology 2000; 42: 653-9.
20. Ferrer, L., Alberola, J., Queralt, M. et al. Clinical anti-inflammatory efficacy of arofylline: a new selective phosphodiesterase-4 inhibitor, in dogs with atopic dermatitis. Veterinary Record 1999; 145: 191-4.
21. Schiffner, R., SchiffnerRohe, J., Gerstenhauer, M. et al. Differences in efficacy between intention-to-treat and per-protocol analyses for patients with psoriasis vulgaris and atopic dermatitis: clinical and pharmacoeconomic implications. British Journal of Dermatology 2001; 144: 1154-60.
22. Gridelli, B., Scanlon, L., Pellicci, R. et al. Cyclosporine metabolism and pharmacokinetics following intravenous and oral administration in the dog. Transplantation 1986; 41: 388-91.
23. Myre, S.A., Schoeder, T.J., Grund, V.R. et al. Critical ketoconazole dosage range for ciclosporin clearance inhibition in the dog. Pharmacology 1991; 43: 233-41.
24. Ryffel, B., Donatsch, P., Madörin, M. et al. Toxicological evaluations of cyclosporin A. Archives of Toxicology 1983; 53: 107-41.
25. Granlund, H., Erkko, P., Reitamo, S. Long-term follow-up of eczema patients treated with cyclosporine. Acta Dermato-Venereologica 1998; 78: 40-3.
26. Grossman, R.M., Chevret, S., Abi-Rached, J. et al. Long-term safety of cyclosporine in the treatment of psoriasis. Archives of Dermatology 1996; 132: 623-9.
27. Vaden, S.L., Breitschwerdt, E.B., Armstrong, P.J. et al. The effects of cyclosporine versus standard care in dogs with naturally occurring glomerulonephritis. Journal of Veterinary Internal Medicine 1995; 9: 259-66.
28. Seibel, W., Yahia, N.A., McCleary, L.B. et al. Cyclosporine-induced gingival overgrowth in beagle dogs. Journal of Oral Pathology and Medicine 1989; 18: 240-5.
29. van Schilfgaarde, R., van der Burg, M.P., van Suylichem, P.T. et al. Interference by cyclosporine with the endocrine function of the canine pancreas. Transplantation 1987; 44: 13-16.
30. Wahlstrom, H.E., Akimoto, R., Endres, D. et al. Recovery and hypersecretion of insulin and reversal of insulin resistance after withdrawal of short-term cyclosporine treatment. Transplantation 1992; 53: 1190-5.
31. Deboer, D.J., Hillier, A. The ACVD task force on canine atopic dermatitis (XV): fundamental concepts in clinical diagnosis. Veterinary Immunology and Immunopathology 2001; 81: 271-6.
32. Ihrke, P.J., Norton, A.L., Ling, G.V. et al. Urinary tract infection associated with long-term corticosteroid administration in dogs with chronic skin diseases. Journal of the American Veterinary Medical Association 1985; 186: 43-6.